Medical Journals

32p]2-iodo-n6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32p]mrs2500), a Novel Radioligand for Quantification of Native P2y1 Receptors.

Authors:
  • Houston Dayle
  • Ohno Michihiro
  • Nicholas Robert A
  • Jacobson Kenneth A
  • Harden T Kendall

From: Department of Pharmacology, University of North Carolina School of Medicine, CB# 7365 Chapel Hill, NC 27599, USA. dhouston@med.unc.edu

British journal of pharmacology

  • Publish Date: Mar 2006
  • ISSN: 0007-1188
  • Volume: 147
  • Issue: 5
  • Pages: 459-67
  • Medium: Print
  • Language: English
  • Citation (JAMA): Houston Dayle, Ohno Michihiro, Nicholas Robert A, et al. 32p]2-iodo-n6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate ([32p]mrs2500), a Novel Radioligand for Quantification of Native P2y1 Receptors.. Br. J. Pharmacol. Mar 2006;147:459-67

Abstract

Analysis of the P2Y family of nucleotide-activated G-protein-coupled receptors has been compromised by the lack of selective high-affinity, high-specific-radioactivity radioligands. We have pursued quantification of the P2Y1 receptor through the development of a series of selective P2Y1 receptor antagonists. Recently, we synthesized 2-iodo-N6-methyl-(N)-methanocarba-2’-deoxyadenosine 3’,5’-bisphosphate (MRS2500), a selective, competitive antagonist that exhibits a Ki of 0.8 nM in competition-binding assays with [3H]MRS2279. A 3’-monophosphate precursor molecule, MRS2608, was radiolabeled at the 5’ position with 32P using polynucleotide kinase and [gamma32P]ATP to yield [32P]MRS2500. [32P]MRS2500 bound selectively to Sf9 insect cell membranes expressing the human P2Y1 receptor (Sf9-P2Y1), but did not detectably bind membranes expressing other P2Y receptors. P2Y1 receptor binding to [32P]MRS2500 was saturable with a KD of 1.2 nM. Agonists and antagonists of the P2Y1 receptor inhibited [32P]MRS2500 binding in Sf9-P2Y1 membranes with values in agreement with those observed in functional assays of the P2Y1 receptor. A high-affinity binding site for [32P]MRS2500 (KD=0.33 nM) was identified in rat brain, which exhibited the pharmacological selectivity of the P2Y1 receptor. Distribution of this binding site varied among rat tissues, with the highest amount of binding appearing in lung, liver, and brain. Among brain regions, distribution of the [32P]MRS2500 binding site varied by six-fold, with the highest and lowest amounts of sites detected in cerebellum and cortex, respectively.Taken together, these data illustrate the synthesis and characterization of a novel P2Y1 receptor radioligand and its utility for examining P2Y1 receptor expression in native mammalian tissues.

Mesh Headings (Keywords): Adenosine Diphosphate, Animals, Brain, Deoxyadenine Nucleotides, Male, Phosphorus Radioisotopes, Radioligand Assay, Rats, Rats, Sprague-Dawley, Receptors, Purinergic P2


Check for Full Text / PubMed Unique Identifier (PMID): 16299552


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.